A Phase 4 interventional study of Placebo and Vilazodone in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 75 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-05-18.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 4, Interventional, and Treatment
Safety and Efficacy of Vilazodone in Major Depressive Disorder
2,805 studies on the registry are indexed under Depressive Disorder, Major; 565 are open to participants now.
This study's enrollment of 1,219 is above the median of 80 across 2,338 interventional studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
First submitted before Forest Laboratories became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a history of meeting DSM-IV-TR criteria for:
Dose-matched placebo capsules, oral administration
Drug: Placebo
Vilazodone tablets, 20 mg per day, oral administration
Drug: Vilazodone
Vilazodone tablets, 40 mg per day, oral administration
Drug: Vilazodone
Matching placebo given orally, once per day
Vilazodone, 20 mg per day, oral administration
Also known as: Viibryd
Vilazodone, 40 mg once per day, oral administration
Also known as: Viibryd
Time to first relapse during the double-blind treatment phase
Time frame: Number of days from the randomization date to the relapse date, up to 28 weeks.
The record gives a start of Apr 2012, a primary completion of Oct 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vilazodone